...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma
【24h】

Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma

机译:T3喉鳞状细胞癌保存方案中的食管喉功能不全生存。

获取原文
获取原文并翻译 | 示例

摘要

Background: We reviewed the outcomes of patients with T3 laryngeal neoplasms with a fixed hemilarynx, a large gross tumor volume or a subglottic extension (SGE), treated with a laryngeal-preservation protocol with induction chemotherapy. Patients and Methods: The study end-points were laryngo-esophageal dysfunction free survival (LEDFS), laryngectomy free survival (LFS), overall survival (OS), and disease freesurvival (DFS). Results: A total of 104 patients were included. The 2-year and 5-year OS rates were 70.4% and 54.5%, respectively. OS and DFS were independent of the treatment modality in the whole cohort (p=0.6546 and p=0.3006, respectively) and in patients with SGE (p=0.529 and p=0.255, respectively). The 2-year and 5-year LEDFS rates were 44.3% and 28.2%, respectively. LEDFS was not associated with initial hemilaryngeal fixation or SGE (p=0.5772 and p=0.0623, respectively). Conclusion: Chemoselection is feasible without compromised oncological or functional outcomes in patients with an initially fixed hemilarynx or subglottic extension.
机译:背景:我们回顾了具有喉罩固定,大肿瘤总量或声门下扩张(SGE)的T3喉肿瘤患者的预后,该治疗采用了保留喉镜的诱导化疗方案。患者和方法:研究终点为喉-食管功能障碍无生存期(LEDFS),喉切除术无生存期(LFS),总生存期(OS)和无疾病生存期(DFS)。结果:共纳入104例患者。 2年和5年OS率分别为70.4%和54.5%。在整个队列(分别为p = 0.6546和p = 0.3006)和SGE患者(分别为p = 0.529和p = 0.255)中,OS和DFS与治疗方式无关。 2年和5年LEDFS率分别为44.3%和28.2%。 LEDFS与最初的鼻咽固定或SGE不相关(分别为p = 0.5772和p = 0.0623)。结论:对于最初固定的喉部或声门下扩张的患者,化学选择是可行的,而不会损害肿瘤或功能结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号